Waldencast PLC（WALD）资讯与事件WALDWaldencast PLC

Waldencast Receives FDA Approval for Obagi saypha ChIQ Injectable Hyaluronic Acid Gel

Waldencast announced that the U.S. Food and Drug Administration has approved Obagi saypha ChIQ injectable hyaluronic acid gel, the latest addition to the Obagi injectable portfolio under the Obagi Medical brand. Developed by Croma-Pharma GmbH, the dermal filler is indicated for cheek augmentation and the correction of midface contour deficiencies in patients over the age of 21. "Obagi saypha ChIQ is a meaningful addition to our integrated aesthetic portfolio - giving practitioners and patients more ways to achieve end-to-end skin transformation with predictable, measurable outcomes, and bringing us closer to our vision of building the world's leading dermatological megabrand," said Michel Brousset, co-founder and CEO of Waldencast.

Canaccord Raises Waldencast Price Target to $3

Canaccord raised the firm's price target on Waldencast to $3 from $2 and keeps a Buy rating on the shares. The firm noted the company announced they have entered into an agreement to sell its Obagi skin care and aesthetics business to Bridgepoint. The transaction is valued up to $460M and comprises $366M in cash, a $10M fixed vendor note, a $20M adjustable vendor note, and up to $64M in earnout payments based on revenue milestones.

Waldencast Sells Obagi Medical Skincare Business for Up to $460M

Waldencast announced that it has entered into a definitive agreement to sell its Obagi Medical dermatological skincare and aesthetics business to Bridgepoint in a transaction valued at up to $460M, marking a significant step in Waldencast's strategy to strengthen its balance sheet and focus on accelerating the global growth of Milk Makeup. The transaction, which has been unanimously approved by disinterested members of the Waldencast Board of Directors, is expected to close within the third quarter of 2026, subject to customary closing conditions, including receipt of required regulatory approvals. The transaction is not subject to a financing condition or a shareholder vote. Concurrent with the completion of the transaction, the company expects to repay its approximately $178M of senior secured term loan to Lumina Capital Management Ltda.